Back
 PP  Vol.3 No.1 , January 2012
Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review
Abstract: The kinases have been intensely studied because of their involvement in regulating essential cellular activation of signaling cascades in response to extracellular and intracellular stimuli to control cell growth, proliferation, and survival. Recent cancer genomic sequencing studies have revealed that many more kinases contribute to tumor genesis and are potential targets for inhibitor drug development intervention. Herein we review recent results that have helped to unravel the indolin-2-ones underlying the confiicting roles of the kinase inhibition regulation. This review focuses on the potential of kinases as a chemotherapeutic target in cancer treatment and highlights important recent advances in the development of indolin-2-ones as kinase inhibitors.
Cite this paper: C. Prakash, P. Theivendren and S. Raja, "Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 62-71. doi: 10.4236/pp.2012.31010.
References

[1]   P. Cohen, “Protein Kinases the Major Drug Targets of the Twenty First Century?” Nature Reviews Drug Discovery, Vol. 1, No. 4, 2002, pp. 309-315. doi:10.1038/nrd773

[2]   M. Krug and A. Hilgeroth, “Recent Advances in the Development of Multi Kinase Inhibitors,” Mini-Reviews in Medicinal Chemistry, Vol. 8, No. 13, 2008, pp. 1312-1327. doi:10.2174/138955708786369591

[3]   T. L. Underiner, B. Ruggeri and D. E. Gingrich, “Development of Vascu-lar Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy,” Current Medicinal Chemistry, Vol. 11, No. 6, 2004, pp. 731-745. doi:10.2174/0929867043455756

[4]   L. Q. Chow and S. Gail Eckhardt, “Sunitinib: From Rational Design to Clinical Efficacy,” Journal of Clinical Oncology, Vol. 25, No. 19, 2007, p. 2858. doi:10.1200/JCO.2006.06.3602

[5]   F. Sandrine, D. George, S. William and R. Eric, “Molecular Basis for Sunitinib Efficacy and Future Clinical Development,” Nature Reviews Drug Discovery, Vol. 6, No. 9, 2007, pp. 734-745. doi:10.1038/nrd2380

[6]   A. L. Cheryl, B. M. Phyllis, L. W. F. Stacey, F. B. Joseph, W. R. Anthony, M. P. Rosenberg, C. J. Henry, K. L. Mitchener, M. K. Klein, J. G. Hintermeister, P. J. Bergman, G. C. Couto, G. N. Mauldin and G. M. Michels, “Multi-Center, Placebo-Controlled, Double-Blind, Randomized Study of Oral Toceranib Phosphate (su11654), a Receptor Tyro-sine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (either Local or Distant) Mast Cell Tumor Following Surgical Excision,” Clinical Cancer Research, Vol. 15, No.

[7]   D. M. McLean, “Methisazone Therapy in Vaccinia Complications,” Annals of the New York Academy of Sciences, Vol. 284, 1977, pp. 118-121. doi:10.1111/j.1749-6632.1977.tb21942.x

[8]   A. O. Donnell, A. Padhani, C. Hayes, A. J. Kakkar, M. Leach, J. M. Trigo, M. Scurr, F. Raynaud, S. Phillips, W. Aherne, A. Hardcastle, P. Workman, A. Hannah and I. Judson, “A Phase I Study of the Angiogenesis Inhibitor SU5416 (Semaxanib) in Solid Tumors, Incorporating Dynamic Contrast MR Pharmacodynamic End Points,” British Journal of Cancer, Vol. 93, No. 8, 2005, pp. 876-883. doi:10.1038/sj.bjc.6602797

[9]   G. F. Matthew, Z. Andrew, W. Richard, V. Ennapadam, L. Eric, H. Lucy, A. Timothy, G. William, F. Martin and G. P. David, “A Phase II Study of SU5416 in Patients with Advanced or Recurrent Head and Neck Cancers,” Invest New Drugs, Vol. 25, 2007, pp. 162-172.

[10]   S. Karsten, F. Florian, V. Robert and H. Wolfgang, “The Protein Tyrosine Kinase Inhibitor SU5614 Inhibits VEGF-Induced Endothelial Cell Sprouting and Induces Growth Arrest and Apoptosis by Inhibition of c-kit in AML Cells,” Experimental Hematology, Vol. 30, No. 7, 2002, pp. 767-773. doi:10.1016/S0301-472X(02)00837-8

[11]   S. Cristiana, V. Lucia, G. Giacomo, T. Jose, M. Irene, L. Anna, B. Alberta, I. Nicoletta, M. Silvia and G. Luca, “Phase I Clinical and Pharmacological Evaluation of the Multi Tyrosine Kinase Inhibitor SU006668 by Chronic Oral Dosing,” European Journal of Cancer, Vol. 42, No. 2, 2006, pp. 171-178. doi:10.1016/j.ejca.2005.09.033

[12]   A. D. Laird, P. Vajkoczy, L. K. Shawver, A. Thurnher, C. Liang, M. Mohammadi, J. Schles Singer, A. Ullrich, S. R. Hub-bard, R. A. Blake, T. A. Fong, L. M. Strawn, L. Sun, C. Tang, R. Hawtin, F. Tang, N. Shenoy, K. P. Hirth, G. McMahon and J. M. Cherrington, “SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumor,” Cancer Research, Vol. 60, 2000, pp. 4152-4160.

[13]   W. Fiedler, G. Giaccone, P. Lasch, I. V. Horst, N. Brega, R. Courtney, A. Abbat-tista, D. R. Shalinsky, C. Bokemeyer and E. Boven, “Phase I Trial of SU14813 in Patients with Advanced Solid Malignancies,” Annals of Oncology, Vol. 22, No. 1, 2011, pp. 195-201. doi:10.1093/annonc/mdq313

[14]   P. Shem, A. D. Laird and D. B. Mendel, “SU14813: A Novel Multiple Receptor Tyrosine Kinase Inhibitor with Potent Antiangiogenic and Antitumor Activity,” Molecular Cancer Therapeutics, Vol. 5, No. 7, 2006, pp. 1774-1782. doi:10.1158/1535-7163.MCT-05-0333

[15]   Z. Yitzhak, V. V. Angelina, M. Michaela, S. Bruno, B. L. Wieslawa, H. G. Richard, S. Nikolaus and M. A. Daniel, “Differential Inhibition Sensitivities of MET Mutants to the Small Molecule Inhibitor SU11274,” Cancer Letters, Vol. 289, No. 2, 2010, pp. 228-236. doi:10.1016/j.canlet.2009.08.017

[16]   W. Xueyan, L. Phuong and L. Congxin, “Potent and Selective Inhibitors of the Met [Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor] Tyrosine Kinase Block HGF/ SF-Induced Tumor Cell Growth and Invasion,” Molecular Cancer Therapeutics, Vol. 2, No. 11, 2003, pp. 1085-1092.

[17]   E. H. Brett, L. B. Carlo and K. Dong-woo, “A Population Pharmacokinetic Meta-Analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Pa-tients,” Clinical Cancer Research, Vol. 15, No. 7, 2009, pp. 2497-2506. doi:10.1158/1078-0432.CCR-08-1893

[18]   E K. Grand, A. J. Chase, C. Heath, A. Rahemtulla and N. C. P. Cross, “Targeting FGFR3 in Multiple Myeloma: Inhibition of t(4;14)-Positive Cells by SU5402 and PD173074,” Leu-kemia, Vol. 18, No. 5, 2004, pp. 962-966. doi:10.1038/sj.leu.2403347

[19]   P. Neela, S. Li, M. Deborah, C. Hui, M. L. Kathleen, L. Phuong, G. M. Katherine, W. Xueyan, R. Audie, T. Danny, A. D. Laird, X. M. Yu, Z. Qingling, T. Cho, M. M. Gerald and H. An-thony, “A Selective and Oral Small Molecule Inhibitor of VEGFR-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability,” Journal of Pharmacology and Experimental Therapeutics, Vol. 306, No. 3, 2003, pp. 838-845.

[20]   R. J. Robert, “Sunitinib: A VEGF and PDGF Receptor Protein Kinase and Angiogenesis Inhibitor,” Biochemical and Biophysical Research Communications, Vol. 356, No. 2, 2007, pp. 323-328. doi:10.1016/j.bbrc.2007.02.156

[21]   D. Nathalie, S. Carl, N. Sonia and C. Serge, “Human B Lymphocytes and Non-Hodgkin’s Lymphoma Cells Become Polyploid in Response to the Protein Kinase Inhibitor SU6656,” Blood Cells, Molecules, and Diseases, Vol. 39, No. 1, 2007, pp. 130-134. doi:10.1016/j.bcmd.2007.02.010

[22]   J. M. Deborah, R. B. Cornelia, C. B. David, U. Ping, H. J. J. Terence, H. K. Sung and G. R. Audie, “SU9516: Biochemical Analysis of cdk Inhibition and Crystal Structure in Complex with cdk2,” Biochemical and Biophysical Research Communications, Vol. 310, No. 3, 2003, pp. 1026-1031. doi:10.1016/j.bbrc.2003.09.114

[23]   M. E. Lane, B. Yu, A. Rice, K. E. Lipson, C. Liang, L. Sun, C. Tang, G. McMahon, R. G. Pestell and S. Wadler, “A Novel cdk2-Selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells,” Cancer Research, Vol. 61, No. 16, 2001, pp. 6170-6177.

[24]   M. Yongsheng, C. Eric, W. Xiaomei, S. Chang, M. M. Gerald and B. J. Longley, “Indolinone Derivative Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells,” Journal of Investigative Dermatology, Vol. 114, 2000, pp. 392-394. doi:10.1046/j.1523-1747.2000.00888.x

[25]   M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, B. K. Yeh, S. R. Hubbard and J. Schlessinger, “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors,” Science, Vol. 276, No. 5314, 1997, pp. 955-960. doi:10.1126/science.276.5314.955

 
 
Top